Annovis Bio, Inc. develops buntanetap, an investigational oral therapy for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. News about ANVS commonly centers on clinical development of buntanetap, peer-reviewed publications, biomarker data, safety findings, and scientific presentations related to the company’s multi-protein approach to neurodegeneration.
Recurring updates also cover intellectual-property protection for buntanetap and related compounds, collaborations that add digital biomarker technology to Parkinson’s disease research, corporate financing, annual financial results, and other public-company developments tied to funding, governance, and clinical-regulatory disclosure.
Annovis (NYSE: ANVS) announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13, 2026 (1:40–2:05 PM, Picasso 4&5).
The talk covers a multi-protein model of Alzheimer’s disease, arguing for targeting amyloid, tau, alpha-synuclein, TDP-43 and other aggregating proteins. The presentation includes a Q&A and highlights Annovis’ lead oral drug, buntanetap, now in a pivotal Phase 3 trial.
Annovis (NYSE: ANVS) published Phase 2/3 results for oral buntanetap in Nature NPJ Dementia showing dose-dependent cognitive improvement in pTau217-positive mild AD patients and biomarker reductions. The randomized 12-week trial (351 patients) found buntanetap safe and well-tolerated, including in ApoE4 carriers. The company is advancing a pivotal Phase 3 in early AD (MMSE 20–28), now ~80% enrolled.
Biomarker changes included lower TDP-43, tau, NfL and reduced inflammatory markers, supporting potential disease-modifying activity; Phase 3 will evaluate effects at 6 and 18 months.
Annovis Bio (NYSE: ANVS) closed an underwritten public offering raising approximately $10 million, plus a $1.5 million board investment, extending cash runway through Q2 2027 to fund a key 6‑month Phase 3 Alzheimer's symptomatic readout and an ensuing NDA submission.
The Phase 3 AD trial is ~75% enrolled; FDA agreed to integrate safety data from AD and PD trials into the AD NDA. An open‑label Parkinson's study is 28% enrolled and includes an AI digital biomarker device for real‑time monitoring.
Annovis (NYSE: ANVS)/b) priced an underwritten offering of of common stock with accompanying warrants at a combined price of $1.90 per share/warrant, expected to raise approximately $10 million in gross proceeds before fees.
Each warrant is exercisable for one share at $2.50, becomes exercisable six months after issuance, and expires five years and six months after issuance. Closing is expected on or about April 10, 2026. Net proceeds will fund Phase 3 development of buntanetap and general corporate purposes.
Annovis (NYSE: ANVS) announced issuance of U.S. Patent No. 12,582,632 B2 for buntanetap covering prevention and treatment of neurological injuries caused by brain infections. The patent covers administration across viral, bacterial, fungal, protozoan and parasitic agents, includes preventive and reversal claims, and extends through 2044.
The company is a Phase 3 clinical-stage developer of buntanetap for neurodegenerative diseases.
Annovis (NYSE: ANVS) announced publication of a historical review of its lead candidate buntanetap in The Scientist on March 31, 2026. The article traces buntanetap's discovery, chemical refinement and clinical progress, and places its development in scientific and historical context.
Clinical status: pivotal Phase 3 in early AD (NCT06709014) is 70% enrolled; PD open‑label extension (NCT07284784) is 20% enrolled.
Annovis Bio (NYSE: ANVS) partnered with NeuroRPM to deploy an FDA-cleared AI digital biomarker platform in its open-label Parkinson’s study (ANVS-25002), a 36-month, 25-site U.S. trial testing buntanetap. The study has enrolled 90 of an estimated 500 patients and combines wearable symptom monitoring with a skin-based alpha-synuclein assay reporting >90% sensitivity and specificity.
The initiative aims to capture real-world, continuous measures of bradykinesia, tremor and dyskinesia and link digital and biological biomarkers to better track treatment response and inform future trial design.
Annovis (NYSE: ANVS) reported fiscal 2025 results and corporate updates focused on clinical progress for buntanetap. Key points: initiation of a pivotal Phase 3 AD trial, 65% enrollment across 83 U.S. sites, an OLE PD study launched, patent protection extended to 2047, and year‑end cash of $19.5M.
Financials: R&D $25.2M, G&A $4.5M, net loss per share $1.40 on 20.6M weighted shares; 27.2M shares outstanding. Cash expected to fund operations into Q3 2026.
Annovis (NYSE: ANVS) announced two presentations at AD/PD™ 2026 in Copenhagen, March 17-21, 2026, covering clinical data for buntanetap in Parkinson’s disease and an update on the pivotal Phase 3 trial in early Alzheimer’s disease.
Presenters and session IDs: Presentation #3581 on PD cognition/biomarkers and Presentation #3582 on a 6- and 18-month randomized Phase 3 trial in early AD, both presented by Cheng Fang, Ph.D.
Annovis Bio (NYSE: ANVS) announced that an independent DSMB issued a positive safety recommendation for 6-month buntanetap data, allowing the pivotal Phase 3 Alzheimer's trial to continue without modification.
The DSMB found no safety concerns, noted alignment with Parkinson's safety data, the trial is 40% enrolled, and key readouts are expected early 2027 (symptomatic) and early 2028 (disease‑modifying).